Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.

ABSTRACT:

Aims

The landmark STICH trial found that surgical revascularization compared to medical therapy alone improved survival in patients with heart failure (HF) of ischaemic aetiology and an ejection fraction (EF) ≤ 35%. However, the interaction between the burden of medical co-morbidities and the benefit from surgical revascularization has not been previously described in patients with ischaemic cardiomyopathy.

Methods and results

The STICH trial (ClinicalTrials.gov Identifier: NCT00023595) enrolled patients ≥ 18 years of age with coronary artery disease amenable to coronary artery bypass grafting (CABG) and an EF ≤ 35%. Eligible participants were randomly assigned 1:1 to receive medical therapy (MED) (n = 602) or MED/CABG (n = 610). A modified Charlson co-morbidity index (CCI)

SUBMITTER: Ambrosy AP 

PROVIDER: S-EPMC6818499 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature